Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (NYSE:BMY)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Analysis of Long-term (Investment) Activity Ratios

Beginner level

Long-term Activity Ratios (Summary)

Bristol-Myers Squibb Co., long-term (investment) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net fixed asset turnover
Net fixed asset turnover (including operating lease, right-of-use asset)
Total asset turnover
Equity turnover

Based on: 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Bristol-Myers Squibb Co.’s net fixed asset turnover ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Bristol-Myers Squibb Co.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Bristol-Myers Squibb Co.’s total asset turnover ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Bristol-Myers Squibb Co.’s equity turnover ratio deteriorated from 2017 to 2018 and from 2018 to 2019.

Net Fixed Asset Turnover

Bristol-Myers Squibb Co., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in millions)
Revenues
Property, plant and equipment
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Illumina Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Zoetis Inc.
Net Fixed Asset Turnover, Sector
Pharmaceuticals & Biotechnology
Net Fixed Asset Turnover, Industry
Health Care

Based on: 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12).

1 2019 Calculation
Net fixed asset turnover = Revenues ÷ Property, plant and equipment
= ÷ =

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Bristol-Myers Squibb Co.’s net fixed asset turnover ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Bristol-Myers Squibb Co., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in millions)
Revenues
 
Property, plant and equipment
Operating lease right-of-use assets
Property, plant and equipment (including operating lease, right-of-use asset)
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Illumina Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Zoetis Inc.
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals & Biotechnology
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care

Based on: 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12).

1 2019 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenues ÷ Property, plant and equipment (including operating lease, right-of-use asset)
= ÷ =

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Bristol-Myers Squibb Co.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.

Total Asset Turnover

Bristol-Myers Squibb Co., total asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in millions)
Revenues
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Illumina Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Zoetis Inc.
Total Asset Turnover, Sector
Pharmaceuticals & Biotechnology
Total Asset Turnover, Industry
Health Care

Based on: 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12).

1 2019 Calculation
Total asset turnover = Revenues ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Bristol-Myers Squibb Co.’s total asset turnover ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.

Equity Turnover

Bristol-Myers Squibb Co., equity turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in millions)
Revenues
Total Bristol-Myers Squibb Company shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Eli Lilly & Co.
Gilead Sciences Inc.
Illumina Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Zoetis Inc.
Equity Turnover, Sector
Pharmaceuticals & Biotechnology
Equity Turnover, Industry
Health Care

Based on: 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12).

1 2019 Calculation
Equity turnover = Revenues ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Bristol-Myers Squibb Co.’s equity turnover ratio deteriorated from 2017 to 2018 and from 2018 to 2019.